What's Happening?
Genentech has announced the results of its Phase III persevERA Breast Cancer study, which evaluated the efficacy of giredestrant in combination with palbociclib for patients with estrogen receptor-positive, HER2-negative, locally advanced or metastatic
breast cancer. The study did not achieve its primary objective of a statistically significant improvement in progression-free survival compared to letrozole plus palbociclib. However, a numerical improvement was observed. The adverse events associated with the giredestrant combination were manageable and consistent with known safety profiles. Despite not meeting the primary endpoint, Genentech remains optimistic about giredestrant's potential as a new standard-of-care endocrine therapy in both early and advanced ER-positive breast cancer. The company plans to continue exploring the combination of giredestrant with a CDK4/6 inhibitor in the adjuvant setting.
Why It's Important?
The results of the persevERA study are significant as they highlight the ongoing challenges in developing effective treatments for ER-positive breast cancer, which accounts for approximately 70% of breast cancer cases. While the study did not meet its primary endpoint, the observed numerical improvement suggests potential benefits that warrant further investigation. The development of new therapies like giredestrant is crucial, given the complexity and resistance issues associated with current endocrine therapies. Successful development could lead to improved outcomes for patients with ER-positive breast cancer, offering a new line of treatment that could delay disease progression and reduce the burden of treatment.
What's Next?
Genentech plans to continue its clinical development program for giredestrant, focusing on its potential use in combination with CDK4/6 inhibitors. The company is also preparing to submit Phase III lidERA data to the FDA in the coming weeks. The full results of the persevERA study will be presented at an upcoming medical meeting, which may provide further insights into the potential of giredestrant as a treatment option. Additionally, Genentech is conducting further studies to explore the efficacy of giredestrant in different settings and combinations, aiming to establish it as a standard-of-care therapy.
